Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting

Published: Apr 24, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that three poster presentations on its lead drug candidate EBI-005 have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting taking place May 5-9, 2013, in Seattle, WA. The presentations will highlight EBI-005 as a new approach to optimize topically applied proteins on the surface of the eye and as the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases, including dry eye disease. Patient enrollment and dosing has been completed in a Phase 1b clinical study of EBI-005 treating patients with dry eye disease; top-line data is expected in the second half of 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news